Schroder Investment Management Group Decreases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Schroder Investment Management Group lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.2% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 81,524 shares of the biopharmaceutical company’s stock after selling 13,477 shares during the quarter. Schroder Investment Management Group’s holdings in Regeneron Pharmaceuticals were worth $58,072,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the stock. State Street Corp increased its stake in shares of Regeneron Pharmaceuticals by 1.3% during the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after purchasing an additional 61,277 shares in the last quarter. Loomis Sayles & Co. L P increased its stake in Regeneron Pharmaceuticals by 33.4% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company’s stock worth $1,122,168,000 after buying an additional 393,997 shares in the last quarter. Amundi raised its holdings in shares of Regeneron Pharmaceuticals by 45.8% during the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock valued at $1,138,074,000 after acquiring an additional 487,489 shares during the last quarter. Norges Bank purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $802,036,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 3.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 695,799 shares of the biopharmaceutical company’s stock worth $495,639,000 after acquiring an additional 22,538 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

REGN has been the topic of a number of research reports. Canaccord Genuity Group lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. Bernstein Bank lowered their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. BMO Capital Markets cut their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a report on Tuesday, February 4th. Sanford C. Bernstein lowered their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Finally, Wells Fargo & Company cut their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a report on Friday, January 10th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $966.88.

Regeneron Pharmaceuticals Price Performance

REGN opened at $634.23 on Tuesday. The stock’s 50-day moving average price is $682.93 and its 200 day moving average price is $791.84. Regeneron Pharmaceuticals, Inc. has a 12-month low of $618.51 and a 12-month high of $1,211.20. The firm has a market cap of $69.34 billion, a price-to-earnings ratio of 16.57, a PEG ratio of 2.34 and a beta of 0.27. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period in the prior year, the firm earned $11.86 earnings per share. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were given a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.56%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.